Search - tctmd.com

Displaying 461 - 480 of 641

Sort: Relevancy | Date

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

News Daily News

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

Michael O'Riordan

April 15, 2020

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

News Daily News ACC 2020

Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT

March 17, 2020

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

March 10, 2020

TCTMD’s Top 10 Most Popular Stories for February 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2020

March 02, 2020

News Daily News

Stick-on Sensor Predicts Heart-Failure Hospitalizations: Pilot Study

February 26, 2020

Trials of New Cancer Drugs Failing to Address Potential CV Risks

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

February 10, 2020

MitraClip in the US: As Coverage Update Looms, Some Questions for REPAIR MR

News Daily News

MitraClip in the US: As Coverage Update Looms, Some Questions for REPAIR MR

January 24, 2020

News Daily News

Transcatheter Tricuspid, Mitral Repair Appear Safe to Combine: Registry Data

January 20, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

The Biggest News of 2019: TCTMD’s Top 10

News Opinion Editor's Corner

The Biggest News of 2019: TCTMD’s Top 10

January 01, 2020

Year in Review: Physicians Pick the Biggest News of 2019

News Features

Year in Review: Physicians Pick the Biggest News of 2019

TCTMD News Team

December 30, 2019

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Diastolic Dysfunction Does Not Negate Health Status Benefits of TAVR

News Daily News

Diastolic Dysfunction Does Not Negate Health Status Benefits of TAVR

November 27, 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

November 22, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

November 11, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.